West Pharma Q2 Profit Jumps 17%, Guides FY EPS to $8.85-$9.05
WST sits 71% above its 52-week low of $211.1.
Summary
West Pharmaceutical Services delivered a strong Q2, with GAAP EPS of $2.15 (up from $1.82) and adjusted EPS of $2.37, beating expectations. Revenue rose 13.8% to $872.3 million, driven by robust demand. The company issued full-year EPS guidance of $8.85-$9.05 and revenue of $3.345B-$3.38B, with the revenue range exceeding consensus. Next quarter guidance calls for EPS of $2.14-$2.24 on revenue of $820M-$835M. This follows a cybersecurity incident in May that was resolved without material impact, and the appointment of a new CEO in June. The strong results and upbeat guidance reinforce the company's growth trajectory in the life sciences sector.
At the time of this announcement, WST was trading at $360.20 on NYSE in the Life Sciences sector, with a market capitalization of approximately $25.3B. The 52-week trading range was $211.10 to $367.66. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: dpa-AFX.